O'Melveny's Zucker Comments on Proposed Abbott Labs Breakup For The Deal Pipeline

10월 20, 2011 O'Melveny Mergers and Acquisitions Practice Group partner Sam Zucker commented on the decision by Abbott Laboratories to split the company into two US$20 billion publicly traded entities for The Deal Pipeline. In the October 20, 2011 story, "Observers Laud Abbott Decision to Break Apart," Zucker says it seems to be a smart move. "These are two very different businesses," Zucker told the Deal. "Arguably they are held back by one another."